=Pacific Biosciences (PACB) reported earnings on Thur 2 Nov 2017 (a/h)

Pacific Biosciences reports EPS in-line, misses on revs; names Kathy Ordoez as Chief Commercial Officer 

• Reports Q3 (Sep) loss of $0.19 per share, in-line with the Capital IQ Consensus of ($0.19); revenues fell 6.3% year/year to $23.54 mln vs the $28.29 mln Capital IQ Consensus.
• Gross profit for the third quarter of 2017 was $8.2 million, resulting in a gross margin of 35%. 
• Pacific Biosciences also named Kathy Ordoez as Chief Commercial Officer (Previously held senior roles at Hoffmann-La Roche, Celera, Quest Diagnostics and RainDance Technologies)